Your browser is no longer supported. Please, upgrade your browser.
FLDM [NASD]
Fluidigm Corporation
Index- P/E- EPS (ttm)-0.90 Insider Own0.90% Shs Outstand76.30M Perf Week-13.41%
Market Cap227.91M Forward P/E- EPS next Y-1.02 Insider Trans0.00% Shs Float75.03M Perf Month-24.47%
Income-67.80M PEG- EPS next Q-0.28 Inst Own91.50% Short Float6.96% Perf Quarter-45.59%
Sales136.90M P/S1.66 EPS this Y24.10% Inst Trans0.05% Short Ratio7.75 Perf Half Y-53.75%
Book/sh1.30 P/B2.18 EPS next Y-8.50% ROA-22.60% Target Price10.00 Perf Year-58.54%
Cash/sh- P/C- EPS next 5Y-8.06% ROE-57.60% 52W Range2.93 - 7.51 Perf YTD-27.55%
Dividend- P/FCF- EPS past 5Y17.50% ROI-25.80% 52W High-62.18% Beta1.27
Dividend %- Quick Ratio1.00 Sales past 5Y3.80% Gross Margin55.00% 52W Low-3.07% ATR0.22
Employees627 Current Ratio1.60 Sales Q/Q-28.60% Oper. Margin-53.40% RSI (14)23.98 Volatility6.45% 6.54%
OptionableYes Debt/Eq0.64 EPS Q/Q-119.20% Profit Margin-49.50% Rel Volume1.19 Prev Close2.98
ShortableYes LT Debt/Eq0.64 EarningsNov 08 AMC Payout- Avg Volume673.39K Price2.84
Recom1.00 SMA20-16.83% SMA50-28.69% SMA200-47.44% Volume799,664 Change-4.70%
Nov-06-19Downgrade Janney Buy → Neutral
Oct-18-19Upgrade UBS Neutral → Buy $14 → $7
Mar-15-19Initiated UBS Neutral $14
Jan-03-19Upgrade Janney Neutral → Buy
Nov-02-18Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated Mizuho Buy $11 → $12
Aug-05-16Reiterated Cantor Fitzgerald Buy $13 → $11
May-05-16Reiterated Mizuho Buy $8 → $11
Apr-12-16Reiterated Leerink Partners Outperform $20 → $15
Jan-07-16Initiated Deutsche Bank Buy $18
Oct-30-15Upgrade Cantor Fitzgerald Hold → Buy $15 → $12
Oct-30-15Reiterated Mizuho Neutral $15 → $8
Aug-27-15Initiated Cantor Fitzgerald Hold
Aug-07-15Reiterated Mizuho Neutral $30 → $15
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
May-08-15Reiterated Maxim Group Buy $52 → $44
May-08-15Downgrade Mizuho Buy → Neutral $50 → $30
May-06-14Reiterated Maxim Group Buy $65 → $52
Apr-23-14Upgrade Mizuho Neutral → Buy $43 → $50
Mar-21-14Reiterated Maxim Group Buy $52 → $65
Jan-11-22 08:00AM  
Dec-07-21 08:30AM  
Nov-16-21 08:30AM  
Nov-13-21 08:33AM  
Nov-11-21 08:30AM  
Nov-09-21 08:11AM  
Nov-08-21 04:02PM  
08:30AM  
Oct-20-21 08:30AM  
Oct-18-21 08:30AM  
Oct-12-21 08:30AM  
Sep-28-21 08:30AM  
Sep-02-21 08:30AM  
Aug-31-21 08:30AM  
Aug-10-21 02:19AM  
Aug-09-21 11:14AM  
Aug-05-21 04:05PM  
09:30AM  
08:35AM  
08:30AM  
Jul-08-21 04:01PM  
Jun-17-21 07:30AM  
May-25-21 02:00PM  
May-24-21 08:30AM  
May-14-21 08:30AM  
May-10-21 01:30PM  
May-06-21 04:05PM  
08:30AM  
Apr-16-21 03:34AM  
Apr-08-21 08:30AM  
Mar-21-21 07:33AM  
Mar-01-21 08:30AM  
Feb-16-21 01:27PM  
Feb-14-21 11:18PM  
Feb-11-21 11:40AM  
07:26AM  
Feb-10-21 05:45PM  
04:28PM  
04:05PM  
04:02PM  
04:02PM  
02:45PM  
Feb-09-21 10:11AM  
08:30AM  
Feb-04-21 04:02PM  
Feb-03-21 12:31PM  
Jan-26-21 08:30AM  
Jan-22-21 11:45AM  
10:57AM  
10:47AM  
07:22AM  
Jan-21-21 04:05PM  
Jan-07-21 04:02PM  
Jan-05-21 08:30AM  
Dec-25-20 01:41AM  
Dec-15-20 04:05PM  
Dec-08-20 07:15AM  
Nov-27-20 08:34AM  
Nov-24-20 08:30AM  
Nov-23-20 11:00AM  
Nov-22-20 01:00PM  
11:37AM  
Nov-20-20 09:54PM  
01:30PM  
12:40PM  
11:15AM  
10:22AM  
10:00AM  
08:52AM  
Nov-19-20 05:15PM  
04:35PM  
12:28PM  
11:00AM  
10:57AM  
10:54AM  
09:49AM  
09:30AM  
08:30AM  
08:00AM  
06:20AM  
Nov-18-20 09:30PM  
03:20PM  
03:12PM  
01:55PM  
01:42PM  
12:15PM  
11:30AM  
11:00AM  
10:40AM  
10:00AM  
09:42AM  
Nov-17-20 10:27PM  
09:00PM  
05:10PM  
04:23PM  
01:30PM  
01:30PM  
01:00PM  
12:30PM  
11:45AM  
Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF XT. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kreger Bradley AllenSVP, Global OperationsNov 20Option Exercise0.007,751089,419Nov 24 06:45 PM
McCracken ColinChief Commercial OfficerNov 20Option Exercise0.006,519065,853Nov 24 06:45 PM
JOG VIKRAMChief Financial OfficerNov 20Option Exercise0.006,8770132,535Nov 24 06:44 PM
Khadder NicholasSVP, Gen. Counsel & SecretaryNov 20Option Exercise0.004,063081,249Nov 24 06:45 PM
Linthwaite Stephen ChristopherPresident & CEONov 20Option Exercise0.0022,4170326,511Nov 24 06:44 PM
Linthwaite Stephen ChristopherPresident & CEOAug 20Option Exercise0.0022,4170315,381Aug 24 07:10 PM
Kreger Bradley AllenSVP, Global OperationsAug 20Option Exercise0.007,753084,348Aug 24 07:10 PM
McCracken ColinChief Commercial OfficerAug 20Option Exercise0.006,519062,857Aug 24 07:11 PM
Khadder NicholasSVP, Gen. Counsel & SecretaryAug 20Option Exercise0.004,062079,199Aug 24 07:09 PM
JOG VIKRAMChief Financial OfficerAug 20Option Exercise0.006,8790128,036Aug 24 07:09 PM
Khadder NicholasSVP, Gen. Counsel & SecretaryMay 20Option Exercise0.0046,250096,918May 24 04:09 PM
Linthwaite Stephen ChristopherPresident & CEOMay 20Option Exercise0.00177,4170380,498May 24 04:09 PM
Kreger Bradley AllenSVP, Global OperationsMay 20Option Exercise0.0057,752096,477May 24 04:09 PM
McCracken ColinChief Commercial OfficerMay 20Option Exercise0.0066,520092,425May 24 04:08 PM
JOG VIKRAMChief Financial OfficerMay 20Option Exercise0.0051,8780139,096May 24 04:08 PM
Kreger Bradley AllenSVP, Global OperationsFeb 20Option Exercise0.0014,923044,847Feb 23 09:59 PM
Linthwaite Stephen ChristopherPresident & CEOFeb 20Option Exercise0.0048,7500196,177Feb 23 09:57 PM
McCracken ColinChief Commercial OfficerFeb 20Option Exercise0.0013,691033,777Feb 23 09:57 PM
JOG VIKRAMChief Financial OfficerFeb 20Option Exercise0.0015,491081,304Feb 23 09:57 PM